Раздел 1.6
1. Strauss S.J., Frezza A.M., Abecassis N., et al. Bone sarcomas: ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(12):1520-1536. doi:10.1016/j.annonc.2021.08.1995.
2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Soft Tissue Sarcoma, Version 2.2023. Published online April 25, 2023.
3. Валиев А.К., Конев А.А., Курильчик А.А., et al. Злокачественные опухоли костей. Malig Tumours. 2023;13(3s2-1):335-355. doi:10.18027/2224-5057-2023-13-3s2-1-335-355
4. Beird H.C., Bielack S.S., Flanagan A.M., et al. Osteosarcoma. Nat Rev Dis Primer. 2022;8(1):77. doi:10.1038/s41572-022-00409-y
5. Anninga J.K., Gelderblom H., Fiocco M., et al. Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? Eur J Cancer Oxf Engl 1990. 2011;47(16):2431-2445. doi:10.1016/j.ejca.2011.05.030
6. Gill J., Gorlick R. Advancing therapy for osteosarcoma. Nat Rev Clin Oncol. 2021;18(10):609-624. doi:10.1038/s41571-021-00519-8
7. Rosen G., Marcove R.C., Huvos A.G., et al. Primary osteogenic sarcoma: Eight-year experience with adjuvant chemotherapy. J Cancer Res Clin Oncol. 1983;106(S1):55-67. doi:10.1007/BF00625054
8. Eilber F., Giuliano A., Eckardt J., Patterson K., Moseley S., Goodnight J. Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol Off J Am Soc Clin Oncol. 1987;5(1):21-26. doi:10.1200/JCO.1987.5.1.21
9. Link M.P., Goorin A.M., Miser A.W., et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med. 1986;314(25):1600-1606. doi:10.1056/NEJM198606193142502
10. Link M.P., Goorin A.M., Horowitz M., et al. Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the Multi-Institutional Osteosarcoma Study. Clin Orthop. 1991;(270):8-14.
11. Bernthal N.M., Federman N., Eilber F.R., et al. Long-term results (>25 years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with high-grade, operable osteosarcoma. Cancer. 2012;118(23):5888-5893. doi:10.1002/cncr.27651
12. Rosen G. Preoperative (neoadjuvant) chemotherapy for osteogenic sarcoma: a ten year experience. Orthopedics. 1985;8(5):659-664. doi:10.3928/0147-7447-19850501-19
13. Bielack S.S., Kempf-Bielack B., Winkler K. Osteosarcoma: relationship of response to preoperative chemotherapy and type of surgery to local recurrence. J Clin Oncol Off J Am Soc Clin Oncol. 1996;14(2):683-684. doi:10.1200/JCO.1996.14.2.683
14. Picci P., Sangiorgi L., Rougraff B.T., Neff J.R., Casadei R., Campanacci M. Relationship of chemotherapy-induced necrosis and surgical margins to local recurrence in osteosarcoma. J Clin Oncol Off J Am Soc Clin Oncol. 1994;12(12):2699-2705. doi:10.1200/JCO.1994.12.12.2699
15. Bielack S.S., Kempf-Bielack B., Delling G., et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol Off J Am Soc Clin Oncol. 2002;20(3):776-790. doi:10.1200/JCO.2002.20.3.776
16. Bacci G., Bertoni F., Longhi A., et al. Neoadjuvant chemotherapy for high-grade central osteosarcoma of the extremity. Histologic response to preoperative chemotherapy correlates with histologic subtype of the tumor. Cancer. 2003;97(12):3068-3075. doi:10.1002/cncr.11456
17. Hauben E.I., Weeden S., Pringle J., Van Marck E.A., Hogendoorn P.C.W. Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup. Eur J Cancer Oxf Engl 1990. 2002;38(9):1218-1225. doi:10.1016/s0959-8049(02)00037-0
18. Petrilli A.S., de Camargo B., Filho V.O, et al. Results of the Brazilian Osteosarcoma Treatment Group Studies III and IV: prognostic factors and impact on survival. J Clin Oncol Off J Am Soc Clin Oncol. 2006;24(7):1161-1168. doi:10.1200/JCO.2005.03.5352
19. Bishop M.W., Chang Y.C., Krailo M.D., et al. Assessing the Prognostic Significance of Histologic Response in Osteosarcoma: A Comparison of Outcomes on CCG-782 and INT0133-A Report From the Children’s Oncology Group Bone Tumor Committee. Pediatr Blood Cancer. 2016;63(10):1737-1743. doi:10.1002/pbc.26034
20. Ruengwanichayakun P., Gambarotti M., Frisoni T., et al. Parosteal osteosarcoma: a monocentric retrospective analysis of 195 patients. Hum Pathol. 2019;91:11-18. doi:10.1016/j.humpath.2019.05.009
21. Grimer R.J., Bielack S., Flege S., et al. Periosteal osteosarcoma — a European review of outcome. Eur J Cancer. 2005;41(18):2806-2811. doi:10.1016/j.ejca.2005.04.052
22. Rosen G., Caparros B., Huvos A.G., et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer. 1982;49(6):1221-1230. doi:10.1002/1097-0142(19820315)49:6<1221::aid-cncr2820490625>3.0.co;2-e
23. Bacci G., Picci P., Ferrari S., et al. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin. Cancer. 1993;72(11):3227-3238. doi:10.1002/1097-0142(19931201)72:11<3227::aid-cncr2820721116>3.0.co;2-c
24. Bacci G., Ferrari S., Bertoni F., et al. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report. J Clin Oncol Off J Am Soc Clin Oncol. 2000;18(24):4016-4027. doi:10.1200/JCO.2000.18.24.4016
25. Yu D., Zhang S., Feng A., et al. Methotrexate, doxorubicin, and cisplatinum regimen is still the preferred option for osteosarcoma chemotherapy: A meta-analysis and clinical observation. Medicine (Baltimore). 2019;98(19):e15582. doi:10.1097/MD.0000000000015582
26. Navid F., Willert J.R., McCarville M.B., et al. Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. Cancer. 2008;113(2):419-425. doi:10.1002/cncr.23586
27. Meyers P.A., Heller G., Healey J., et al. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol Off J Am Soc Clin Oncol. 1992;10(1):5-15. doi:10.1200/JCO.1992.10.1.5
28. Provisor A.J., Ettinger L.J., Nachman J.B., et al. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children’s Cancer Group. J Clin Oncol Off J Am Soc Clin Oncol. 1997;15(1):76-84. doi:10.1200/JCO.1997.15.1.76
29. Saeter G., Alvegård T.A., Elomaa I., Stenwig A.E., Holmström T., Solheim O.P. Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate: a Scandinavian Sarcoma Group study. J Clin Oncol Off J Am Soc Clin Oncol. 1991;9(10):1766-1775. doi:10.1200/JCO.1991.9.10.1766
30. Winkler K., Beron G., Delling G., et al. Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol Off J Am Soc Clin Oncol. 1988;6(2):329-337. doi:10.1200/JCO.1988.6.2.329
31. Souhami R.L., Craft A.W., Van der Eijken J.W., et al. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet Lond Engl. 1997;350(9082):911-917. doi:10.1016/S0140-6736(97)02307-6
32. Smeland S., Müller C., Alvegard T.A., et al. Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur J Cancer Oxf Engl 1990. 2003;39(4):488-494. doi:10.1016/s0959-8049(02)00747-5
33. Marina N.M., Smeland S., Bielack S.S., et al. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. Lancet Oncol. 2016;17(10):1396-1408. doi:10.1016/S1470-2045(16)30214-5
34. Goorin A.M., Schwartzentruber D.J., Devidas M., et al. Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol Off J Am Soc Clin Oncol. 2003;21(8):1574-1580. doi:10.1200/JCO.2003.08.165
35. Bramwell V.H., Burgers M., Sneath R., et al. A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup. J Clin Oncol Off J Am Soc Clin Oncol. 1992;10(10):1579-1591. doi:10.1200/JCO.1992.10.10.1579
36. van Dalen E.C., de Camargo B. Methotrexate for high-grade osteosarcoma in children and young adults. Cochrane Database Syst Rev. 2009;(1):CD006325. doi:10.1002/14651858.CD006325.pub2
37. Daw N.C., Neel M.D., Rao B.N., et al. Frontline treatment of localized osteosarcoma without methotrexate: results of the St. Jude Children’s Research Hospital OS99 trial. Cancer. 2011;117(12):2770-2778. doi:10.1002/cncr.25715
38. Harris M.B., Gieser P., Goorin A.M., et al. Treatment of metastatic osteosarcoma at diagnosis: a Pediatric Oncology Group Study. J Clin Oncol Off J Am Soc Clin Oncol. 1998;16(11):3641-3648. doi:10.1200/JCO.1998.16.11.3641
39. Meyers P.A., Heller G., Healey J.H., et al. Osteogenic sarcoma with clinically detectable metastasis at initial presentation. J Clin Oncol Off J Am Soc Clin Oncol. 1993;11(3):449-453. doi:10.1200/JCO.1993.11.3.449
40. Ferguson W.S., Harris M.B., Goorin A.M., et al. Presurgical window of carboplatin and surgery and multidrug chemotherapy for the treatment of newly diagnosed metastatic or unresectable osteosarcoma: Pediatric Oncology Group Trial. J Pediatr Hematol Oncol. 2001;23(6):340-348. doi:10.1097/00043426-200108000-00004
41. Ferrari S., Briccoli A., Mercuri M., et al. Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival. J Clin Oncol Off J Am Soc Clin Oncol. 2003;21(4):710-715. doi:10.1200/JCO.2003.03.141
42. Italiano A., Mir O., Mathoulin-Pelissier S., et al. Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020;21(3):446-455. doi:10.1016/S1470-2045(19)30825-3
43. Davis L.E., Bolejack V., Ryan C.W., et al. Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma. J Clin Oncol Off J Am Soc Clin Oncol. 2019;37(16):1424-1431. doi:10.1200/JCO.18.02374
44. Raciborska A., Bilska K. Sorafenib in patients with progressed and refractory bone tumors. Med Oncol. 2018;35(10). doi:10.1007/s12032-018-1180-x
45. Brennan B., Kirton L., Marec-Bérard P., et al. Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial. Lancet Lond Engl. 2022;400(10362):1513-1521. doi:10.1016/S0140-6736(22)01790-1
46. Whelan J., Le Deley M.C., Dirksen U., et al. High-Dose Chemotherapy and Blood Autologous Stem-Cell Rescue Compared With Standard Chemotherapy in Localized High-Risk Ewing Sarcoma: Results of Euro-E.W.I.N.G.99 and Ewing-2008. J Clin Oncol Off J Am Soc Clin Oncol. 2018;36(31):JCO2018782516. doi:10.1200/JCO.2018.78.2516
47. Womer R.B., West D.C., Krailo M.D., et al. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children’s Oncology Group. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(33):4148-4154. doi:10.1200/JCO.2011.41.5703
48. Leavey P.J., Laack N.N., Krailo M.D., et al. Phase III Trial Adding Vincristine-Topotecan-Cyclophosphamide to the Initial Treatment of Patients With Nonmetastatic Ewing Sarcoma: A Children’s Oncology Group Report. J Clin Oncol Off J Am Soc Clin Oncol. 2021;39(36):4029-4038. doi:10.1200/JCO.21.00358
49. Smith M.A., Altekruse S.F., Adamson P.C., Reaman G.H., Seibel N.L. Declining childhood and adolescent cancer mortality. Cancer. 2014;120(16):2497-2506. doi:10.1002/cncr.28748
50. Craft A., Cotterill S., Malcolm A., et al. Ifosfamide-containing chemotherapy in Ewing’s sarcoma: The Second United Kingdom Children’s Cancer Study Group and the Medical Research Council Ewing’s Tumor Study. J Clin Oncol Off J Am Soc Clin Oncol. 1998;16(11):3628-3633. doi:10.1200/JCO.1998.16.11.3628
51. Donaldson S.S., Torrey M., Link M.P., et al. A multidisciplinary study investigating radiotherapy in Ewing’s sarcoma: end results of POG #8346. Pediatric Oncology Group. Int J Radiat Oncol Biol Phys. 1998;42(1):125-135. doi:10.1016/s0360-3016(98)00191-6
52. Kushner B.H., Meyers P.A., Gerald W.L., et al. Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing’s sarcoma, in children and young adults. J Clin Oncol Off J Am Soc Clin Oncol. 1995;13(11):2796-2804. doi:10.1200/JCO.1995.13.11.2796
53. Pinkerton C.R., Bataillard A., Guillo S., Oberlin O., Fervers B., Philip T. Treatment strategies for metastatic Ewing’s sarcoma. Eur J Cancer Oxf Engl 1990. 2001;37(11):1338-1344. doi:10.1016/s0959-8049(01)00131-9
54. Sandoval C., Meyer W.H., Parham D.M., et al. Outcome in 43 children presenting with metastatic Ewing sarcoma: the St. Jude Children’s Research Hospital experience, 1962 to 1992. Med Pediatr Oncol. 1996;26(3):180-185. doi:10.1002/(SICI)1096-911X(199603)26:3<180::AID-MPO6>3.0.CO;2-G
55. Hayes F.A., Thompson E.I., Parvey L., et al. Metastatic Ewing’s sarcoma: remission induction and survival. J Clin Oncol Off J Am Soc Clin Oncol. 1987;5(8):1199-1204. doi:10.1200/JCO.1987.5.8.1199
56. Craft A.W., Cotterill S.J., Bullimore J.A., Pearson D. Long-term results from the first UKCCSG Ewing’s Tumour Study (ET-1). United Kingdom Children’s Cancer Study Group (UKCCSG) and the Medical Research Council Bone Sarcoma Working Party. Eur J Cancer Oxf Engl 1990. 1997;33(7):1061-1069. doi:10.1016/s0959-8049(97)00043-9
57. Deméocq F., Oberlin O., Benz-Lemoine E., et al. Initial chemotherapy including ifosfamide in the management of Ewing’s sarcoma: preliminary results. A protocol of the French Pediatric Oncology Society (SFOP). Cancer Chemother Pharmacol. 1989;24 Suppl 1:S45-47. doi:10.1007/BF00253240
58. Cangir A., Vietti T.J., Gehan E.A., et al. Ewing’s sarcoma metastatic at diagnosis. Results and comparisons of two intergroup Ewing’s sarcoma studies. Cancer. 1990;66(5):887-893. doi:10.1002/1097-0142(19900901)66:5<887::aid-cncr2820660513>3.0.co;2-r
59. Paulussen M., Ahrens S., Craft A.W., et al. Ewing’s tumors with primary lung metastases: survival analysis of 114 (European Intergroup) Cooperative Ewing’s Sarcoma Studies patients. J Clin Oncol Off J Am Soc Clin Oncol. 1998;16(9):3044-3052. doi:10.1200/JCO.1998.16.9.3044
60. Marina N.M., Pappo A.S., Parham D.M., et al. Chemotherapy dose-intensification for pediatric patients with Ewing’s family of tumors and desmoplastic small round-cell tumors: a feasibility study at St. Jude Children’s Research Hospital. J Clin Oncol Off J Am Soc Clin Oncol. 1999;17(1):180-190. doi:10.1200/JCO.1999.17.1.180
61. Paulussen M., Ahrens S., Burdach S., et al. Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies. European Intergroup Cooperative Ewing Sarcoma Studies. Ann Oncol Off J Eur Soc Med Oncol. 1998;9(3):275-281. doi:10.1023/a:1008208511815
62. Brunetto A.L., Castillo L.A., Petrilli A.S., et al. Carboplatin in the treatment of Ewing sarcoma: Results of the first Brazilian collaborative study group for Ewing sarcoma family tumors-EWING1. Pediatr Blood Cancer. 2015;62(10):1747-1753. doi:10.1002/pbc.25562
63. Paulussen M., Craft A.W., Lewis I., et al. Results of the EICESS-92 Study: two randomized trials of Ewing’s sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(27):4385-4393. doi:10.1200/JCO.2008.16.5720
64. Miser J.S., Krailo M.D., Tarbell N.J., et al. Treatment of metastatic Ewing’s sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide--a Children’s Cancer Group and Pediatric Oncology Group study. J Clin Oncol Off J Am Soc Clin Oncol. 2004;22(14):2873-2876. doi:10.1200/JCO.2004.01.041
65. Wexler L.H., DeLaney T.F., Tsokos M., et al. Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing’s sarcoma family of tumors. Cancer. 1996;78(4):901-911. doi:10.1002/(SICI)1097-0142(19960815)78:4<901::AID-CNCR30>3.0.CO;2-X
66. Grier H.E., Krailo M.D., Tarbell N.J., et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing’s sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med. 2003;348(8):694-701. doi:10.1056/NEJMoa020890
67. Koch R., Gelderblom H., Haveman L., et al. High-Dose Treosulfan and Melphalan as Consolidation Therapy Versus Standard Therapy for High-Risk (Metastatic) Ewing Sarcoma. J Clin Oncol Off J Am Soc Clin Oncol. 2022;40(21):2307-2320. doi:10.1200/JCO.21.01942
68. Haveman L.M., van Ewijk R., van Dalen E.C., et al. High-dose chemotherapy followed by autologous haematopoietic cell transplantation for children, adolescents, and young adults with primary metastatic Ewing sarcoma. Cochrane Database Syst Rev. 2021;9(9):CD011405. doi:10.1002/14651858.CD011405.pub2
69. Dirksen U., Brennan B., Le Deley M.C., et al. High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008. J Clin Oncol Off J Am Soc Clin Oncol. 2019;37(34):3192-3202. doi:10.1200/JCO.19.00915
70. Raciborska A., Bilska K., Drabko K., et al. Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory Ewing sarcoma. Pediatr Blood Cancer. 2013;60(10):1621-1625. doi:10.1002/pbc.24621
71. Dogan I., Iribas A., Ahmed M.A., Basaran M. Efficacy of the VIT (vincristine, irinotecan and temozolomide) regimen in adults with metastatic Ewing sarcoma. J Chemother Florence Italy. 2023;35(4):343-347. doi:10.1080/1120009X.2022.2104295
72. Xu J., Xie L., Sun X., et al. Longer versus Shorter Schedules of Vincristine, Irinotecan, and Temozolomide (VIT) for Relapsed or Refractory Ewing Sarcoma: A Randomized Controlled Phase 2 Trial. Clin Cancer Res Off J Am Assoc Cancer Res. 2023;29(6):1040-1046. doi:10.1158/1078-0432.CCR-22-3546
73. Rodriguez-Galindo C., Billups C.A., Kun L.E., et al. Survival after recurrence of Ewing tumors: the St Jude Children’s Research Hospital experience, 1979-1999. Cancer. 2002;94(2):561-569. doi:10.1002/cncr.10192
74. Barker L.M., Pendergrass T.W., Sanders J.E., Hawkins D.S. Survival after recurrence of Ewing’s sarcoma family of tumors. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(19):4354-4362. doi:10.1200/JCO.2005.05.105
75. McCabe M.G., Kirton L., Khan M., et al. Results of the second interim assessment of rEECur, an international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES). J Clin Oncol. 2020;38(15_suppl):11502-11502. doi:10.1200/JCO.2020.38.15_suppl.11502
76. Xu J., Xie L., Sun X., et al. Longer versus Shorter Schedules of Vincristine, Irinotecan, and Temozolomide (VIT) for Relapsed or Refractory Ewing Sarcoma: A Randomized Controlled Phase 2 Trial. Clin Cancer Res Off J Am Assoc Cancer Res. 2023;29(6):1040-1046. doi:10.1158/1078-0432.CCR-22-3546
77. Attia S., Bolejack V., Ganjoo K.N., et al. A phase II trial of regorafenib in patients with advanced Ewing sarcoma and related tumors of soft tissue and bone: SARC024 trial results. Cancer Med. 2023;12(2):1532-1539. doi:10.1002/cam4.5044
78. Duffaud F., Blay J.Y., Le Cesne A., et al. Regorafenib in patients with advanced Ewing sarcoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre Phase II study. Br J Cancer. 2023;129(12):1940-1948. doi:10.1038/s41416-023-02413-9
79. Tap W.D., Demetri G., Barnette P., et al. Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(15):1849-1856. doi:10.1200/JCO.2011.37.2359
80. Pappo A.S., Patel S.R., Crowley J., et al. R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(34):4541-4547. doi:10.1200/JCO.2010.34.0000
81. Juergens H., Daw N.C., Geoerger B., et al. Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(34):4534-4540. doi:10.1200/JCO.2010.33.0670
82. DuBois S.G., Krailo M.D., Glade-Bender J., et al. Randomized Phase III Trial of Ganitumab With Interval-Compressed Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma: A Report From the Children’s Oncology Group. J Clin Oncol Off J Am Soc Clin Oncol. 2023;41(11):2098-2107. doi:10.1200/JCO.22.01815
83. Wyman J.J., Hornstein A.M., Meitner P.A., et al. Multidrug resistance-1 and p-glycoprotein in human chondrosarcoma cell lines: expression correlates with decreased intracellular doxorubicin and in vitro chemoresistance. J Orthop Res Off Publ Orthop Res Soc. 1999;17(6):935-940. doi:10.1002/jor.1100170619
84. Terek R.M., Schwartz G.K., Devaney K., et al. Chemotherapy and P-glycoprotein expression in chondrosarcoma. J Orthop Res Off Publ Orthop Res Soc. 1998;16(5):585-590. doi:10.1002/jor.1100160510
85. van Oosterwijk J.G., Herpers B., Meijer D., et al. Restoration of chemosensitivity for doxorubicin and cisplatin in chondrosarcoma in vitro: BCL-2 family members cause chemoresistance. Ann Oncol Off J Eur Soc Med Oncol. 2012;23(6):1617-1626. doi:10.1093/annonc/mdr512
86. van Oosterwijk J.G., Meijer D., van Ruler M.A.J.H., et al. Screening for potential targets for therapy in mesenchymal, clear cell, and dedifferentiated chondrosarcoma reveals Bcl-2 family members and TGFβ as potential targets. Am J Pathol. 2013;182(4):1347-1356. doi:10.1016/j.ajpath.2012.12.036
87. de Jong Y., Monderer D., Brandinelli E., et al. Bcl-xl as the most promising Bcl-2 family member in targeted treatment of chondrosarcoma. Oncogenesis. 2018;7(9):74. doi:10.1038/s41389-018-0084-0
88. Italiano A., Mir O., Cioffi A., et al. Advanced chondrosarcomas: role of chemotherapy and survival. Ann Oncol Off J Eur Soc Med Oncol. 2013;24(11):2916-2922. doi:10.1093/annonc/mdt374
89. van Maldegem A.M., Gelderblom H., Palmerini E., et al. Outcome of advanced, unresectable conventional central chondrosarcoma. Cancer. 2014;120(20):3159-3164. doi:10.1002/cncr.28845
90. Mitchell A.D., Ayoub K., Mangham D.C., Grimer R.J., Carter S.R., Tillman R.M. Experience in the treatment of dedifferentiated chondrosarcoma. J Bone Joint Surg Br. 2000;82(1):55-61. doi:10.1302/0301-620x.82b1.9020
91. Staals E.L., Bacchini P., Mercuri M., Bertoni F. Dedifferentiated chondrosarcomas arising in preexisting osteochondromas. J Bone Joint Surg Am. 2007;89(5):987-993. doi:10.2106/JBJS.F.00288
92. Hompland I., Ferrari S., Bielack S., et al. Outcome in dedifferentiated chondrosarcoma for patients treated with multimodal therapy: Results from the EUROpean Bone Over 40 Sarcoma Study. Eur J Cancer Oxf Engl 1990. 2021;151:150-158. doi:10.1016/j.ejca.2021.04.017
93. Dantonello T.M., Int-Veen C., Leuschner I., et al. Mesenchymal chondrosarcoma of soft tissues and bone in children, adolescents, and young adults: experiences of the CWS and COSS study groups. Cancer. 2008;112(11):2424-2431. doi:10.1002/cncr.23457
94. Cesari M., Bertoni F., Bacchini P., Mercuri M., Palmerini E., Ferrari S. Mesenchymal chondrosarcoma. An analysis of patients treated at a single institution. Tumori. 2007;93(5):423-427. doi:10.1177/030089160709300503
95. Frezza A.M., Cesari M., Baumhoer D., et al. Mesenchymal chondrosarcoma: prognostic factors and outcome in 113 patients. A European Musculoskeletal Oncology Society study. Eur J Cancer Oxf Engl 1990. 2015;51(3):374-381. doi:10.1016/j.ejca.2014.11.007
96. Nooij M.A., Whelan J., Bramwell V.H.C., et al. Doxorubicin and cisplatin chemotherapy in high-grade spindle cell sarcomas of the bone, other than osteosarcoma or malignant fibrous histiocytoma: a European Osteosarcoma Intergroup Study. Eur J Cancer Oxf Engl 1990. 2005;41(2):225-230. doi:10.1016/j.ejca.2004.08.026
97. La Rocca R.V., Morgan K.W., Paris K., Baeker T.R. Recurrent chondrosarcoma of the cranial base: a durable response to ifosfamide-doxorubicin chemotherapy. J Neurooncol. 1999;41(3):281-283. doi:10.1023/a:1006154904014
98. Italiano A., Mir O., Cioffi A., et al. Advanced chondrosarcomas: role of chemotherapy and survival. Ann Oncol Off J Eur Soc Med Oncol. 2013;24(11):2916-2922. doi:10.1093/annonc/mdt374
99. van Maldegem A.M., Gelderblom H., Palmerini E., et al. Outcome of advanced, unresectable conventional central chondrosarcoma. Cancer. 2014;120(20):3159-3164. doi:10.1002/cncr.28845
100. Dantonello T.M., Int-Veen C., Leuschner I., et al. Mesenchymal chondrosarcoma of soft tissues and bone in children, adolescents, and young adults: experiences of the CWS and COSS study groups. Cancer. 2008;112(11):2424-2431. doi:10.1002/cncr.23457
101. Tawbi H.A., Burgess M., Bolejack V., et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017;18(11):1493-1501. doi:10.1016/S1470-2045(17)30624-1
102. Van Der Graaf W.T., Blay J.Y., Chawla S.P., et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. 2012;379(9829):1879-1886. doi:10.1016/S0140-6736(12)60651-5
103. Duffaud F., Italiano A., Bompas E., et al. Efficacy and safety of regorafenib in patients with metastatic or locally advanced chondrosarcoma: Results of a non-comparative, randomised, double-blind, placebo controlled, multicentre phase II study. Eur J Cancer Oxf Engl 1990. 2021;150:108-118. doi:10.1016/j.ejca.2021.03.039
104. Kostine M., Cleven A.H., de Miranda N.F.C.C., Italiano A., Cleton-Jansen A.M., Bovée J.V.M.G. Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype. Mod Pathol Off J U S Can Acad Pathol Inc. 2016;29(9):1028-1037. doi:10.1038/modpathol.2016.108
105. Paoluzzi L., Cacavio A., Ghesani M., et al. Response to anti-PD1 therapy with nivolumab in metastatic sarcomas. Clin Sarcoma Res. 2016;6:24. doi:10.1186/s13569-016-0064-0
106. Eder J.P., Doroshow D.B., Do K.T., et al. Clinical Efficacy of Olaparib in IDH1/IDH2-Mutant Mesenchymal Sarcomas. JCO Precis Oncol. 2021;5:466-472. doi:10.1200/PO.20.00247
107. Schrage Y.M., Briaire-de Bruijn I.H., de Miranda N.F.C.C., et al. Kinome profiling of chondrosarcoma reveals SRC-pathway activity and dasatinib as option for treatment. Cancer Res. 2009;69(15):6216-6222. doi:10.1158/0008-5472.CAN-08-4801
108. Schuetze S.M., Bolejack V., Choy E., et al. Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor. Cancer. 2017;123(1):90-97. doi:10.1002/cncr.30379
109. Grignani G., Palmerini E., Stacchiotti S., et al. A phase 2 trial of imatinib mesylate in patients with recurrent nonresectable chondrosarcomas expressing platelet-derived growth factor receptor-α or -β: An Italian Sarcoma Group study. Cancer. 2011;117(4):826-831. doi:10.1002/cncr.25632
110. Meijer D., Gelderblom H., Karperien M., Cleton-Jansen A.M., Hogendoorn P.C.W., Bovee J.V.M.G. Expression of aromatase and estrogen receptor alpha in chondrosarcoma, but no beneficial effect of inhibiting estrogen signaling both in vitro and in vivo. Clin Sarcoma Res. 2011;1(1):5. doi:10.1186/2045-3329-1-5
111. Freed D.M., Sommer J., Punturi N. Emerging target discovery and drug repurposing opportunities in chordoma. Front Oncol. 2022;12:1009193. doi:10.3389/fonc.2022.1009193
112. Ferraresi V., Nuzzo C., Zoccali C., et al. Chordoma: clinical characteristics, management and prognosis of a case series of 25 patients. BMC Cancer. 2010;10:22. doi:10.1186/1471-2407-10-22
113. Stacchiotti S., Marrari A., Tamborini E., et al. Response to imatinib plus sirolimus in advanced chordoma. Ann Oncol Off J Eur Soc Med Oncol. 2009;20(11):1886-1894. doi:10.1093/annonc/mdp210
114. Casali P.G., Messina A., Stacchiotti S., et al. Imatinib mesylate in chordoma. Cancer. 2004;101(9):2086-2097. doi:10.1002/cncr.20618
115. Stacchiotti S., Longhi A., Ferraresi V., et al. Phase II study of imatinib in advanced chordoma. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(9):914-920. doi:10.1200/JCO.2011.35.3656
116. Stacchiotti S., Morosi C., Lo Vullo S., et al. Imatinib and everolimus in patients with progressing advanced chordoma: A phase 2 clinical study. Cancer. 2018;124(20):4056-4063. doi:10.1002/cncr.31685
117. Hindi N., Casali P.G., Morosi C., et al. Imatinib in advanced chordoma: A retrospective case series analysis. Eur J Cancer Oxf Engl 1990. 2015;51(17):2609-2614. doi:10.1016/j.ejca.2015.07.038
118. Liu C., Jia Q., Wei H., et al. Apatinib in patients with advanced chordoma: a single-arm, single-centre, phase 2 study. Lancet Oncol. 2020;21(9):1244-1252. doi:10.1016/S1470-2045(20)30466-6
119. Singhal N., Kotasek D., Parnis F.X. Response to erlotinib in a patient with treatment refractory chordoma. Anticancer Drugs. 2009;20(10):953-955. doi:10.1097/CAD.0b013e328330c7f0
120. Bompas E., Le Cesne A., Tresch-Bruneel E., et al. Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO). Ann Oncol Off J Eur Soc Med Oncol. 2015;26(10):2168-2173. doi:10.1093/annonc/mdv300
121. George S., Merriam P., Maki R.G., et al. Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(19):3154-3160. doi:10.1200/JCO.2008.20.9890
122. Jacob H.E. Chemotherapy for cranial base tumors. J Neurooncol. 1994;20(3):327-335. doi:10.1007/BF01053047
123. Azzarelli A., Quagliuolo V., Cerasoli S., et al. Chordoma: natural history and treatment results in 33 cases. J Surg Oncol. 1988;37(3):185-191. doi:10.1002/jso.2930370311
124. Chen S., Ulloa R., Soffer J., et al. Chordoma: A Comprehensive Systematic Review of Clinical Trials. Cancers. 2023;15(24):5800. doi:10.3390/cancers15245800
125. Blay J.Y., Chevret S., Le Cesne A., et al. Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial. Lancet Oncol. 2023;24(8):892-902. doi:10.1016/s1470-2045(23)00282-6
126. Wang X., Chen Z., Li B., Fan J., Xu W., Xiao J. Immunotherapy as a Promising Option for the Treatment of Advanced Chordoma: A Systemic Review. Cancers. 2022;15(1):264. doi:10.3390/cancers15010264